Source: New York Times
The vice president of a cancer center is facing intense criticism as the organization re-examines its deals with for-profit companies.
Vice President of the Memorial Sloan Kettering Cancer Center Dr. Gregory Raskin must pay the hospital nearly $1.4 million after profiting from stock options.
The cancer center start-up went public about a week ago, but officials at Memorial Sloan Kettering stated policies would be changed so that all proceeds would solely benefit the hospital and research.
In a released statement, the Manhattan-based center announced greater restrictions of employee interactions with for-profit companies.
Memorial Sloan Kettering currently specializes in experimental cancer treatments for children.
Read Full Story: New York Times